GSK (GLAXF) Total Stockholders Equity: $23,803 Mil (As of Mar. 2026)


GLAXF GSK PLC GLAXF
69 GF Score
Price $26.29
GF Value $21.83
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is GSK Total Stockholders Equity?

GSK GLAXF -2.63% 69 Total Stockholders Equity is $23,803 Mil as of Mar. 2026. GuruFocus rates GLAXF with a GF Score™ of 69/100 and a GF Value™ of $21.83 (Modestly Overvalued). The stock has 1 warning sign investors should review.

GSK's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $23,803 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. GSK's Book Value per Share for the quarter that ended in Mar. 2026 was $5.92. The ratio of a company's debt over equity can be used to measure how leveraged this company is. GSK's Debt-to-Equity for the quarter that ended in Mar. 2026 was 1.07.

GSK  (OTCPK:GLAXF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

GSK's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(23802.667-0)/4020.267
=5.92

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

GSK's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(6725.333 + 18682.667) / 23802.667
=1.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GSK Total Stockholders Equity Related Terms

GSK Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for GSK's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GSK Total Stockholders Equity Chart

GSK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20,019.95 12,908.65 16,894.94 17,283.19 21,923.70

GSK Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18,290.70 20,069.20 21,821.62 21,923.70 23,802.67
GLAXF
69GF Score
GSK PLC GLAXF
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $23,803 Mil mean?
GSK (GLAXF) has a Total Stockholders Equity of $23,803 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for GSK and its competitors.
Is GSK's Total Stockholders Equity too high?
GSK's current Total Stockholders Equity is $23,803 Mil. Overall, GSK has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's Total Stockholders Equity compare to LLY and JNJ?
GSK's Total Stockholders Equity of $23,803 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for GSK and its competitors. GSK's current Total Stockholders Equity is $23,803 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (GLAXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.83, compared to a current price of $26.29 — trading 20.4% above its estimated fair value. The current Total Stockholders Equity is $23,803 Mil. GSK's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For GSK (GLAXF), the current Total Stockholders Equity is $23,803 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GSK (GLAXF) Overvalued in 2026?

Based on GuruFocus' analysis, GSK stock appears to be overvalued. The current stock price of $26.29 is trading 20.4% above its estimated GF Value™ of $21.83. GuruFocus considers GSK to be Modestly Overvalued.

Key valuation signals for GLAXF:

  • Total Stockholders Equity: $23,803 Mil
  • GF Value™: $21.83 vs. price of $26.29 (20.4% above fair value)
  • GF Score™: 69/100 with 1 warning sign

No single metric tells the full story. See the GLAXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GSK Business Description

Address 79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
69GF Score

Get the complete analysis for GLAXF

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.29
Price
$21.83
GF Value